The updated label has also been approved by Canadian and European Union regulatory agencies, according to an Aug. 21 news release from Abbott.
The change is based on findings from the ARIES-HM3 study, published Nov. 11 in JAMA, which showed patients who did not use aspirin after receiving a HeartMate 3 device had almost 40% fewer complications compared to patients who did use aspirin.
Aspirin is routinely used as part of a heart patient’s blood thinning regimen to reduce the risk of blood clot formation.
Patients who did not use aspirin after receiving a HeartMate 3 implant also experienced fewer days in the hospital, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
